Stuttgart - Delayed Quote EUR

Blueprint Medicines Corp (2L9.SG)

107.90

-0.60

(-0.55%)

At close: January 31 at 9:34:02 PM GMT+1

Why Blueprint Medical (BPMC) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Blueprint Medical (NASDAQ:BPMC) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a […]

Insider Monkey 5 days ago

BPMC
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Zacks 16 days ago

BMRN

INCY

HALO
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.

Zacks 17 days ago

BPMC
5 Biotech Stocks Worth Adding to Your Portfolio in 2025

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks 17 days ago

HALO

BMRN

EXEL
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?

Blueprint Medicines (BPMC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 17 days ago

BPMC
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor

AYVAKIT's multibillion-dollar potential and BLU-808 breakthroughs drive BPMC's meteoric rise in biotech innovation.

GuruFocus.com 18 days ago

BPMC
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Blueprint Medicines Corporation (Nasdaq: BPMC) today provided a 2025 corporate outlook and strategy for continued growth leveraging the company's proven R&D and commercial capabilities.

PR Newswire 19 days ago

BPMC
High Growth Tech Stocks to Watch in January 2025

Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 24%, with earnings expected to grow by 15% per annum in the coming years. In this context of robust market performance and anticipated growth, identifying high growth tech stocks involves looking for companies with innovative solutions and strong potential to capitalize on emerging trends.

Simply Wall St. 23 days ago

BPMC

PSTG

NET
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).

PR Newswire last month

BPMC
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes. The datasets, which include one oral presentation and three poster presentations, will be reported

PR Newswire last month

BPMC
Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has remained flat, yet it is up 32% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability in a rapidly evolving sector.

Simply Wall St. last month

BPMC

WMG

ROKU
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 2 months ago

BPMC
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune mast cells. In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic mastocytosis (ISM). In the third quarter of 2024, Ayvakit reported net product revenues of $128.2 million, including $113.1 million in the U.S. and $15.1 million ex-U.S., representing 136% growth year over year. Blueprint Medicines anticipate

Benzinga 2 months ago

BPMC
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report

It's been a good week for Blueprint Medicines Corporation ( NASDAQ:BPMC ) shareholders, because the company has just...

Simply Wall St. 2 months ago

BPMC
High Growth Tech Stocks to Watch in November 2024

Over the last 7 days, the United States market has dropped 1.6%, but over the longer term, it has risen by 30% in the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential for sustained revenue expansion in alignment with these market trends.

Simply Wall St. 2 months ago

APPN

BPMC

CGNX
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations

Blueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2024 Results Key Financial Results Revenue: US$128.2m (up 127% from...

Simply Wall St. 2 months ago

BPMC
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.

Zacks 2 months ago

BPMC
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...

Blueprint Medicines Corp (BPMC) reports a 137% revenue growth for AYVAKIT and raises its 2024 revenue guidance, showcasing strong financial performance and strategic advancements.

GuruFocus.com 2 months ago

BPMC
Q3 2024 Blueprint Medicines Corp Earnings Call

Q3 2024 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents 3 months ago

BPMC
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 8.25% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

BPMC

Performance Overview

Return	2L9.SG	S&P 500
YTD	+27.57%	+2.26%
1-Year	+39.23%	+22.65%
3-Year	+76.19%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Blueprint Medicines Corp (2L9.SG)

Why Blueprint Medical (BPMC) Is Skyrocketing Now

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?

Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

High Growth Tech Stocks to Watch in January 2025

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Exploring Three High Growth Tech Stocks in the United States

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report

High Growth Tech Stocks to Watch in November 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations

BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...

Q3 2024 Blueprint Medicines Corp Earnings Call

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Performance Overview